Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-035953
Filing Date
2021-05-26
Accepted
2021-05-26 16:46:49
Documents
2
Period of Report
2021-05-24

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1577
2 POA DOCUMENT poa.txt EX-24.3_988358 3069
  Complete submission text file 0001209191-21-035953.txt   6217
Mailing Address C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Business Address
Alles Mark J (Reporting) CIK: 0001538897 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38871 | Film No.: 21966974

Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Issuer) CIK: 0001595893 (see all company filings)

EIN.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations